| __timestamp | Bausch Health Companies Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 10337679 |
| Thursday, January 1, 2015 | 2682700000 | 18187286 |
| Friday, January 1, 2016 | 2810000000 | 24758063 |
| Sunday, January 1, 2017 | 2582000000 | 23666957 |
| Monday, January 1, 2018 | 2473000000 | 30099855 |
| Tuesday, January 1, 2019 | 2554000000 | 64947625 |
| Wednesday, January 1, 2020 | 2367000000 | 186363444 |
| Friday, January 1, 2021 | 2624000000 | 272611040 |
| Saturday, January 1, 2022 | 2625000000 | 358782000 |
| Sunday, January 1, 2023 | 2917000000 | 409864000 |
Unlocking the unknown
In the ever-evolving landscape of the pharmaceutical industry, understanding spending patterns is crucial. Over the past decade, Bausch Health Companies Inc. and Intra-Cellular Therapies, Inc. have showcased contrasting approaches to their Selling, General, and Administrative (SG&A) expenses.
Bausch Health, a giant in the sector, has consistently allocated a significant portion of its budget to SG&A, with a peak in 2023, marking a 44% increase from 2014. This reflects their strategy to maintain a robust market presence. In contrast, Intra-Cellular Therapies, a smaller player, has seen a staggering 3,865% rise in SG&A expenses over the same period, highlighting their aggressive growth and expansion efforts.
These trends underscore the diverse strategies companies employ to navigate the competitive pharmaceutical landscape, offering insights into their operational priorities and market positioning.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Intra-Cellular Therapies, Inc.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Bausch Health Companies Inc.
Biogen Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Intra-Cellular Therapies, Inc. and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Catalyst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Bausch Health Companies Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Bausch Health Companies Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
MorphoSys AG and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Bausch Health Companies Inc. vs Merus N.V.: SG&A Expense Trends
Comparing SG&A Expenses: Bausch Health Companies Inc. vs Agios Pharmaceuticals, Inc. Trends and Insights